• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌肝移植候选者微血管侵犯的预测因素——特别参考去γ-羧基凝血酶原的血清水平

The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.

作者信息

Shirabe Ken, Itoh Shinji, Yoshizumi Tomoharu, Soejima Yuji, Taketomi Akinobu, Aishima Shin-Ichi, Maehara Yoshihiko

机构信息

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

J Surg Oncol. 2007 Mar 1;95(3):235-40. doi: 10.1002/jso.20655.

DOI:10.1002/jso.20655
PMID:17323337
Abstract

The microvascular invasion of cancer cells (mvi) is a good prognostic factor after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC). The aim of this study is to predict mvi in patients with HCC who were candidates for OLT. We studied 218 patients with HCC resections who had HCC without any extrahepatic metastases and vascular invasion detected during preoperative evaluation. We analyzed the clinico-pathological data of these patients to predict the mvi presence. The mvi prediction scoring system was made and the accuracy of this system was examined using independent clinico-pathologic factors. The size and histological grade of the tumor were significantly correlated with the mvi. The des-gamma-carboxy prothrombin (DCP) is a mvi predictor. The sensitivity of our mvi prediction system was 75% and the specificity was 85% in 32 patients who underwent living-donor liver transplantations for HCC. Our study shows that besides the tumor size and histological grade, a measurement of the serum DCP levels could be a good predictor for mvi. A tumor biopsy and a preoperative measurement of DCP could improve the selection of patients with HCC for OLT. Our scoring system for mvi provides us a precise prediction of the presence of mvi.

摘要

癌细胞微血管侵犯(MVI)是肝细胞癌(HCC)原位肝移植(OLT)术后的一个良好预后因素。本研究的目的是预测OLT候选患者中HCC的MVI情况。我们研究了218例接受HCC切除术的患者,这些患者在术前评估中未发现任何肝外转移和血管侵犯。我们分析了这些患者的临床病理数据以预测MVI的存在。制定了MVI预测评分系统,并使用独立的临床病理因素检验了该系统的准确性。肿瘤大小和组织学分级与MVI显著相关。去γ-羧基凝血酶原(DCP)是MVI的一个预测指标。在32例因HCC接受活体肝移植的患者中,我们的MVI预测系统的敏感性为75%,特异性为85%。我们的研究表明,除肿瘤大小和组织学分级外,血清DCP水平的检测可能是MVI的一个良好预测指标。肿瘤活检和术前DCP检测可改善HCC患者OLT的选择。我们的MVI评分系统为我们提供了对MVI存在情况的精确预测。

相似文献

1
The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.肝细胞癌肝移植候选者微血管侵犯的预测因素——特别参考去γ-羧基凝血酶原的血清水平
J Surg Oncol. 2007 Mar 1;95(3):235-40. doi: 10.1002/jso.20655.
2
New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma.预测肝细胞癌患者微血管侵犯的新评分系统。
Liver Int. 2014 Jul;34(6):937-41. doi: 10.1111/liv.12459. Epub 2014 Jan 24.
3
Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value.活体供肝肝移植治疗肝细胞癌:特别参考术前异常凝血酶原值
Transplant Proc. 2005 Mar;37(2):1177-9. doi: 10.1016/j.transproceed.2004.12.030.
4
Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.甲胎蛋白和去γ-羧基凝血酶原在接受肝切除术的肝细胞癌患者中的意义。
Ann Surg Oncol. 2009 Oct;16(10):2795-804. doi: 10.1245/s10434-009-0618-y. Epub 2009 Aug 11.
5
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.慢性肝炎、肝硬化和肝细胞癌患者的去γ-羧基凝血酶原、甲胎蛋白和甲胎蛋白-L3
J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8. doi: 10.1111/j.1440-1746.2008.05395.x. Epub 2008 Apr 19.
6
Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.肝细胞癌患者癌组织及非癌肝组织中的去γ-羧基凝血酶原
Int J Oncol. 2003 May;22(5):969-75.
7
Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.使用修订的酶免疫测定试剂盒测定的血清去γ-羧基凝血酶原水平,其相对于孤立性肝细胞癌的临床病理特征具有更高的灵敏度。
Cancer. 2000 Feb 1;88(3):544-9.
8
Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.采用高敏电化学发光系统检测血清去γ-羧基凝血酶原水平的序贯波动模式,作为肝硬化患者肝细胞癌的早期预测标志物。
Int J Mol Med. 2002 Mar;9(3):245-50.
9
New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation.肝细胞癌微血管侵犯的新病理分层:预测活体肝移植后的预后
Transplantation. 2015 Jun;99(6):1236-42. doi: 10.1097/TP.0000000000000489.
10
Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.去γ-羧基凝血酶原和肿瘤大小对活体肝移植后肝细胞癌复发的影响
Transplantation. 2009 Feb 27;87(4):531-7. doi: 10.1097/TP.0b013e3181943bee.

引用本文的文献

1
Association of Serum Levels and Immunohistochemical Labelling of Des-Gamma-Carboxy-Prothrombin in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.肝细胞癌肝移植患者血清去γ-羧基凝血酶原水平与免疫组化标记的相关性
Diagnostics (Basel). 2024 Apr 25;14(9):894. doi: 10.3390/diagnostics14090894.
2
The Usefulness of Vitamin K-Dependent Proteins in the Diagnosis of Colorectal Carcinoma.维生素 K 依赖性蛋白在结直肠癌诊断中的作用。
Int J Mol Sci. 2024 May 3;25(9):4997. doi: 10.3390/ijms25094997.
3
MASLD-Related HCC-Update on Pathogenesis and Current Treatment Options.
与代谢相关脂肪性肝病相关的肝细胞癌——发病机制与当前治疗选择的最新进展
J Pers Med. 2024 Mar 30;14(4):370. doi: 10.3390/jpm14040370.
4
Habitat-based radiomics enhances the ability to predict lymphovascular space invasion in cervical cancer: a multi-center study.基于影像组学的研究提高了预测宫颈癌淋巴管间隙浸润的能力:一项多中心研究。
Front Oncol. 2023 Oct 26;13:1252074. doi: 10.3389/fonc.2023.1252074. eCollection 2023.
5
Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes.早期肝细胞癌的管理:实现最佳治疗效果的挑战与策略
J Liver Cancer. 2023 Sep;23(2):300-315. doi: 10.17998/jlc.2023.08.27. Epub 2023 Sep 21.
6
Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery.肝切除术后甲胎蛋白异质体 Ⅱ 及分泌状态对肝癌早期复发的影响:开腹手术与腹腔镜手术的比较
Cancer Med. 2023 Sep;12(17):17866-17877. doi: 10.1002/cam4.6422. Epub 2023 Aug 18.
7
Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment.评估肝细胞癌局部区域治疗后的治疗反应:可用的血清学和影像学评估工具综述
JGH Open. 2023 Apr 3;7(4):249-260. doi: 10.1002/jgh3.12879. eCollection 2023 Apr.
8
Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma.PIVKA-II 在肝癌肝移植患者术后监测中的作用。
Sci Rep. 2023 Apr 6;13(1):5621. doi: 10.1038/s41598-023-32879-9.
9
Diagnostic Performance of Extrahepatic Protein Induced by Vitamin K Absence in the Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.维生素K缺乏诱导的肝细胞癌肝外蛋白的诊断性能:一项系统评价和荟萃分析
Diagnostics (Basel). 2023 Feb 21;13(5):816. doi: 10.3390/diagnostics13050816.
10
Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?肝细胞癌的肝移植:我们应如何提高标准?
Cancers (Basel). 2022 Jan 14;14(2):419. doi: 10.3390/cancers14020419.